JPRN-C000000258未知未知
Effects of octreotide LAR treatment on QOL, clinical symptoms and endocrinological data in patients with acromegaly or pituitary gigantism - Effects of octreotide LAR treatment on QOL in acromegalic patients
Kansai Study Groups for Hypothalamic and Pituitary Diseases0 个研究点目标入组 50 人开始时间: 2005年10月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have previous history of hypersensitivity for elements of Octreotide. 2) Patients whose serum bilirubin or serum creatinine concentration exceeds three times of the upper level of normal ranges. 3) Patients whose AST(GOT) or ALT(GPT) concentration exceeds five times of the upper level of normal ranges.
研究者
相似试验
进行中（未招募）
1 期
The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured surgically. - Pre-operative Octreotide LAR for AcromegalyEUCTR2005-003496-20-GBOxford Radcliffe Hospitals NHS trust
已完成
4 期
Research study of QOL with leukotriene receptor antagonist ,pranlukast in asthmatic patients by use of Asthma Health Questionnaire-Japan QOL (AHQ-JAPAN QOL)AsthmaJPRN-UMIN000000724Asthma QOL Research Study Group1,500
进行中（未招募）
1 期
Clinical-imaging study assessing the value of biological parameters obtained through multimodality molecular and functional imaging (differences in 68Ga-octreotate and 18FDG uptake, changes in diffusion weighted magnetic resonance imaging and 177Lu-octreotate dosimetry) for the prediction of treatment outcome in advanced refractory gastroenteropancreatic neuroendocrine tumors.Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative intent.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2012-003666-41-BEJules Bordet Institute52
进行中（未招募）
1 期
Is treatment with octreotide effective in patients with head-and-neck paraganglioma? - octreotide in head and neck paragangliomaPatients with head-and-neck paragangliomaEUCTR2006-002603-13-NLeiden University Medical Center30
已完成
不适用
octuria QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron studyJPRN-UMIN000024234Department of Urology, school of medicine, Shinshu university120